In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Polymerix Corp.

Latest From Polymerix Corp.

Bioabsorbable Therapeutics Inc.

Bioabsorbable Therapeutics, a start-up built around technology developed at Rutgers University, expects to begin conducting clinical trials on its bioabsorbable stent. The company, which is constructing the stents with polymers that contain non-sterioidal anti-inflammatories, is targeting the coronary market.
Medical Device Platform Technologies

Start-Up Previews (2/05)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Convergence: What's Next at the Nexus?, features profiles of Direct-Haler, EndoBionics, Polymerix and X-Cell Medical. Plus these Start-Ups across Health Care: Discovery Genomics, FoldRx and Neuronetics.

Polymerix Corp.

Polymerix Corp. has developed a unique, proprietary polymerization technology that turns a drug into its own biodegradable delivery vehicle, essentially a Self-Delivering Drug. The technology should enable the polymerization of many already-approved drugs, enabling more controlled and efficient delivery, while creating new therapeutic entities that have robust intellectual property protection.
BioPharmaceutical Medical Device

Convergence: What's Next at the Nexus?

Convergence is the great hope of pharmaceutical and device companies hoping to enter into new high growth markets with differentiated products. Drug-eluting stents turned a stagnant product into a thriving $6 billion market, and now companies are trying to find the next large opportunity that combines devices and drugs. They're looking at many kinds of implantable devices that incorporate biomaterials and drugs to achieve site specific drug delivery, in cardiovascular disease, peripheral vascular disease, ophthalmology, orthopedics, wound healing, and anti-infection.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Dental & Oral Products
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Polymerix Corp.
  • Senior Management
  • Karen Giroux, PhD, CEO
  • Contact Info
  • Polymerix Corp.
    Phone: (732) 457-9300
    10 Knightsbridge Road
    Piscataway, NJ 08854